Neurocrine Biosciences
NBIX
#1431
Rank
A$21.67 B
Marketcap
A$215.55
Share price
-0.62%
Change (1 day)
12.78%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$9.99

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$9.41. In 2025 the company made an earnings per share (EPS) of A$6.76 an increase over its 2024 EPS that were of A$4.74.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$9.9947.87%
2025A$6.7642.6%
2024A$4.7433.07%
2023A$3.5657.76%
2022A$2.2669.47%
2021A$1.33-78.21%
2020A$6.11990%
2019A$0.5681.82%
2018A$0.31-113.5%
2017A-$2.290.62%
2016A-$2.2757.28%
2015A-$1.4425.61%
2014A-$1.1518.84%
2013A-$0.97-1085.71%
2012A$0.09816

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.84-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$2.88-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$39.58 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$1.29-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.85-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$4.91-47.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$41.93-545.60%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.67-71.62%๐Ÿ‡ฌ๐Ÿ‡ง UK